[Accepted Manuscript] Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. by Manchanda, R. et al.
LSHTM Research Online
Manchanda, R.; Patel, S.; Gordeev, V.S.; Antoniou, A.C.; Smith, S.; Lee, A.; Hopper, J.L.; MacInnis,
R.J.; Turnbull, C.; Ramus, S.J.; +5 more... Gayther, S.A.; Pharoah, P.D.P.; Menon, U.; Jacobs, I.;
Legood, R.; (2018) [Accepted Manuscript] Cost-effectiveness of Population-Based BRCA1, BRCA2,
RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Journal of the National Cancer Institute. ISSN 0027-8874 DOI: https://doi.org/10.1093/jnci/djx265
Downloaded from: http://researchonline.lshtm.ac.uk/4648808/
DOI: https://doi.org/10.1093/jnci/djx265
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
1 
 
JNCI 17-0764R2 
Article 
 
Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, 
PALB2 mutation testing in unselected general population women 
 
*Ranjit Manchanda1,2,3, Shreeya Patel1,4, Vladimir S Gordeev5, Antonis C Antoniou6, Shantel 
Smith4, Andrew Lee6, John L Hopper7, Robert J. MacInnis7,  Clare Turnbull8, Susan J 
Ramus9,10,, Simon A Gayther11, Paul DP Pharoah6, Usha Menon3, Ian Jacobs3,12 and Rosa 
Legood4.  
 
Affiliations 
1Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of 
London, London EC1M 6BQ, UK 
2Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, 
London E1 1BB, UK 
3Gynaecological Cancer Research Centre, Department of Women’s Cancer, Institute for 
Women’s Health, University College London, London, UK, W1T 7DN 
4Department of Health Services Research and Policy, London School of Hygiene and 
Tropical Medicine, London, WC1H 9SH, UK 
5Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical 
Medicine, London, WC1E 7HT, UK 
6Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research 
Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK  
2 
 
7Centre for Epidemiology & Biostatistics, Melbourne School of Population & Global Health, 
Faculty of Medicine, Dentistry & Health Sciences, University of Melbourne, Victoria 3010 
Australia 
8Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK  
9Faculty of Medicine, School of Women’s and Children’s Health, University of New South 
Wales, Sydney, Australia 
10The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Australia 
11Cedars Sinai Medical Centre, Los Angeles, CA 90048, USA 
12University of New South Wales, Australia, Level 1, Chancellery Building, UNSW Sydney 
NSW 2052  
 
*Corresponding Author- 
Dr Ranjit Manchanda MD, MRCOG, PhD 
Clinical Senior Lecturer, Consultant Gynaecological Oncologist  
Barts Cancer Institute, Queen Mary University of London 
Room 4, Basement, Old Anatomy Building, Charterhouse Square, London EC1M 6BQ 
Department of Gynaecological Oncology 
Bartshealth NHS Trust, Royal London Hospital 
10th Floor, South Block, Whitechapel Road, London E1 1BB,  
Fax: 0203 594 2792 
Email: r.manchanda@qmul.ac.uk  
 
 
  
3 
 
ABSTRACT  
BACKGROUND 
The cost-effectiveness of population-based panel-testing for high and moderate penetrance 
ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We evaluate cost-
effectiveness of population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
mutation testing compared to clinical-criteria/family history (FH) testing in unselected 
general population women. 
METHODS 
A decision-analytic model compared lifetime costs and effects of Criteria/FH-based 
BRCA1/BRCA2 testing is compared with BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
testing in those fulfilling Clinical-criteria/strong FH of cancer (≥10% BRCA1/BRCA2 
probability), and all women ≥30 years. Analyses are presented for UK and USA populations. 
Identified carriers undergo risk-reducing salpingo-oophorectomy. BRCA1/BRCA2/PALB2 
carriers can opt for MRI/mammography, chemoprevention or risk-reducing mastectomy. 
One-way and probabilistic sensitivity analysis (PSA) enabled model uncertainty evaluation. 
Outcomes include OC, BC, and additional heart disease deaths. Quality-adjusted life-years 
(QALYs), OC incidence, BC incidence, and incremental cost-effectiveness ratio (ICER) were 
calculated. . The time horizon is lifetime and perspective is payer  
RESULTS 
Compared to Clinical-criteria/FH-based BRCA1/BRCA2 testing, Clinical-criteria/FH-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is cost-effective: 
ICER=£7629.65/QALY or $49,282.19/QALY (0.04 days life-expectancy gained). 
Population-based testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is 
the most cost-effective strategy compared to current policy: ICER=£21,599.96/QALY or 
$54,769.78/QALY (9.34 or 7.57days life-expectancy gained). At £30,000/QALY and 
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$100,000/QALY willingness-to-pay thresholds population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 panel-testing is the preferred strategy in 
83.7% and 92.7% PSA simulations; and Criteria/FH-based panel testing is preferred in 16.2% 
and 5.8% simulations respectively.   Population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% BC and 
3.2%/4.88% OC in UK/USA women: 657/655 OC-cases and 2420/2386 BC cases prevented 
per million. 
CONCLUSIONS 
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-
effective than any Clinicalcriteria/FH-based strategy. Clinicalcriteria/FH-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-effective than 
BRCA1/BRCA2 testing alone. 
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INTRODUCTION 
Our existing healthcare structure is directed predominantly towards treatment rather than 
illness prevention. Advances in genomic medicine are being used to guide novel cancer 
treatment strategies. However, it also offers the opportunity to deliver a new population-
based predictive, preventive, personalized, and participatory (P4) medicine strategy for 
cancer prevention. Traditionally ovarian cancer (OC)/breast cancer (BC) prevention has been 
targeted at high-risk individuals like BRCA1/BRCA2 mutation carriers. At-risk mutation 
carriers can opt for: risk-reducing salpingo-oophorectomy (RRSO) to reduce their OC-risk 
(1,2), MRI/mammography screening, risk-reducing mastectomy (RRM) (3), or 
chemoprevention with selective estrogen-receptor-modulators (SERM) to reduce their BC-
risk (4), as well as pre-implantation genetic-diagnosis (PGD) (5). Identification of mutation 
carriers (e.g. BRCA1/BRCA2) at high-risk of OC/BC has involved genetic-testing affected 
individuals or those from high-risk families in specialised genetics clinics. Clinical-
criteria/family-history (FH) are surrogates for BRCA probability with testing offered above a 
certain threshold. However, clinical-criteria/FH-based testing is only moderately effective at 
identifying mutations and has poor ability to rule out the absence of one (6). We (7) and 
others (8,9) have shown that this approach misses >50% mutation carriers. Given the 
effective options available for OC and BC risk management/prevention, this raises serious 
questions about the adequacy of a Clinical-criteria/FH-based approach. Additionally lately, 
newer intermediate/moderate risk OC-genes RAD51C,(10) RAD51D(11) and BRIP1(12) 
(OC-risks ~5-9%), have been identified and their penetrance estimates validated (13,14). 
Furthermore, our recent modelling work strongly suggests that RRSO would be cost-effective 
at ≥4-5% OC-risk (15,16). This enables clinical-utility and supports implementation of 
clinical testing for these gene mutations. Amongst the newer moderate-risk BC-genes, 
PALB2 is the one that confers non-syndromic quasi-Mendelian susceptibility to BC (BC-
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risk=44%) (17) for which equivalent interventions (RRM/breast-MRI) are now offered to 
mutation carriers. ATM, CHEK-2 have lower moderate risks (RR~1.5-2) which don’t justify 
RRM. Testing for these though commercially available, is not currently routinely undertaken 
in clinical practice (18,19). 
The limitations of Clinical-criteria/FH-based ascertainment can be overcome by 
population-based testing. Next-generation sequencing technologies (20,21) with high-
throughput multiplex panel-testing, falling costs, and advances in computational 
bioinformatics has made population-testing feasible. In a prospective randomised trial we 
showed that compared to FH-based testing, population-based BRCA1/BRCA2 testing in 
Ashkenazi-Jews(AJ) is acceptable, feasible, can be undertaken in a community setting, 
doesn’t harm psychological health/quality-of-life, identifies >50% additional carriers, reduces 
BC-&-OC incidence, and is extremely cost-effective (incremental-cost-effectiveness-ratio 
(ICER)=-£2079/quality-adjusted-life-year (QALY)) (7,22). While, there is good evidence to 
support a change in the clinical paradigm from Clinical-criteria/FH to population-based 
testing in Ashkenazi-Jews (23), a population-based approach has not yet been properly 
evaluated in the non-Jewish general population. A health-economic assessment is crucial for 
evaluating and comparing the efficacy of different health interventions. This helps allocate 
resources across interventions, and set policy to improve population health. Here we use a 
decision-analysis model to compare the costs-&-effects of Clinical-criteria/FH and 
population-testing approaches for the known high and moderate penetrance OC/BC gene 
mutations: BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2.  
 
METHODS 
Ethics approval: This analysis was approved under the ethics approval obtained for the 
Genetic Cancer Prediction through Population Screening (GCaPPS) study, from the Institute 
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of Child Health/ Great Ormond Street Hospital Research Ethics Committee: REC Reference 
number 08/H0713/44.  
Decision Model 
A decision-analytic model (Figure 1) was developed to compare the lifetime costs-&-
effects of genetically testing all non-Jewish women ≥30 years for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations compared with the current practice of clinical-
criteria/FH-based testing (based on ≥10% BRCA1/BRCA2 mutation probability alone) (19). 
We present separate analyses for both UK and USA populations. The standard clinical-
criteria/FH-based testing for BRCA1/BRCA2 mutations is compared in an incremental fashion 
to (Strategy-A): Clinical-criteria/FH-based panel testing for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations and (Strategy-B): Population-
testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations. The model assumes 
all women in the population-screening arm and only those fulfilling clinical/FH-criteria in the 
FH-arm are offered genetic-counselling and genetic-testing. We assume 71% will uptake 
genetic-testing (from GCaPPS study) (7). The cost of pre-test counselling is included (24,25). 
BRCA1/BRCA2 negative women are tested for RAD51C/RAD51D/BRIP1/PALB2 mutations 
(from the same DNA sample). A detailed description of all model assumptions is given in 
Supplementary Table 1. The model incorporates the increased risk of cardiovascular 
mortality (absolute increase=3.03%) reported with pre-menopausal bilateral-oophorectomy in 
women who don’t take hormone replacement therapy (HRT) (26,27). Model outcomes 
included OC, BC and excess deaths from heart disease. As per National Institute of Health 
and Care Excellence(NICE) economic evaluation guidelines, costs and outcomes are 
discounted at 3.5% (28). 
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Probabilities 
We use the most up-to date prevalence estimates for BRCA1/BRCA2 (29) and RAD51C, 
RAD51D (14), BRIP1 (13), and PALB2 (30). The probability of having a positive FH or 
fulfilling clinical criteria for non-AJ genetic testing is obtained from previously unpublished 
unselected control population data from the Australian Breast Cancer Family Registry 
(ABCFR). The different pathway probabilities are specified in Table 1 (explanation in 
Supplementary Table 2). Cancer incidence was estimated by summing the probabilities of 
pathways ending in OC or BC. The possibility of both OC and BC occurring simultaneously 
is rare and presumed close to zero. The potential population impact was calculated by 
translating reduction in BC and OC incidence obtained across the population of non-AJ 
UK/USA women. 
 
Costs 
All costs (Supplementary Table 3) are reported at 2014 prices (31) and derived from a 
healthcare system/payer’s perspective. Costs were converted wherever needed using the 
Hospital and Community Health Service Index (32). As per NICE recommendations future 
healthcare costs not associated with OC/BC or cardiovascular disease were not considered 
(28).  
 
Life-years 
The analysis has a lifetime time-horizon covering lifetime risks as well as long-term 
consequences. Female lifetables from the Office of National Statistics (UK women) and 
SEER (USA women) were used for life expectancy data for women not developing OC/BC 
(33). To simplify the analysis we used average estimates for ages of onset and survival for 
BRCA1/BRCA2 related BC and OC. Details of ages of onset and survival estimates used are 
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in Supplementary Table 4. The average ages for BC/OC were 44.4/59.6 years respectively 
for BRCA1+BRCA2 carriers (34). The median ages of onset of sporadic OC/BC were 68/60 
and 63/62 years in the UK and USA populations respectively (from CRUK/SEER) (35-37). 
OC/BC outcomes were modelled using 10-year survival data.  
 
Quality-adjusted-life-years (QALYs) 
QALYs are recommended by NICE as the most suitable summary measure for economic 
evaluation of health outcomes. It adjusts changes in length-of-life, by potential alterations in 
quality-of-life and thus reflects both mortality and health-related quality-of-life effects (28). 
QALY=(Survival in life-years)x(Utility-weight). Calculating QALYs requires knowledge of 
utility weights for each health state in the model. ‘Utility weight’ is an adjustment for quality-
of-life. It indicates an individual’s preference for specific health state where ‘1’=perfect 
health and ‘0’=death. The utility-scores used are described in Supplementary-Table 5.  
 
Analysis 
Figure 1 illustrates the decision-model. Path probabilities (Supplementary-Figure 1) were 
multiplied to calculate each branch probability. The total costs-and-effects in terms of life-
years and QALYs were estimated by weighting the values for each branch by the branch 
probability. The ICER was estimated by dividing the difference in cost by the difference in 
effect between strategies. ICER=(Cost A–Cost B)/(Effect A–Effect B). This ICER obtained is 
compared with the cost-effectiveness willingness-to-pay (WTP) thresholds of NICE 
<£30000/QALY (38) (UK analysis) and USA $100,000/QALY (39,40) (USA analysis) to 
determine whether or not population screening for all women can be cost effective compared 
with clinical-criteria/FH-based testing. Additional scenario analyses were also undertaken: (a) 
no benefit of reduction in BC-risk; (b) varying genetic-testing costs to define UK and USA 
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cost-thresholds for cost-effectiveness; (c) higher all-cause mortality from premenopausal 
oophorectomy, and (d) lower RRSO/RRM uptake.  
Sensitivity analyses explored uncertainty in results and robustness of the model. In a 
one-way sensitivity analysis, each model parameter is varied individually to evaluate impact 
on results. Probabilities/utility weights were varied according to 95% confidence-
intervals/range, where available, or by +/-10%. Costs were varied by +/-30%. Given, model 
parameters/variables are likely to vary in parallel rather than independently, probabilistic 
sensitivity analysis (PSA) was also undertaken (28,41). It permits variables to be varied 
simultaneously across their distributions and is recommended by NICE (28). The PSA was 
fitted with appropriate distributions recommended in the literature (probabilities=beta; 
costs=gamma; utilities=log-normal) (42). A cost-effectiveness acceptability curve plotted the 
result of 10,000 simulations for all strategies. It depicts the proportion of cost-effective 
simulations for each strategy at the various WTP thresholds. The sum of the (cost-effective) 
proportions for all strategies taken together at any given WTP threshold is always=1. 
 
RESULTS 
The comparison of decision model outcomes of the three different testing strategies for 
undiscounted and discounted lifetime costs, life-years(survival), and QALYs is given for both 
UK and US women in Table 2. Discounting reduces the overall cost difference as well as 
gain in life-years/QALYs. This is because future costs/outcomes are adjusted by discounting 
and cost-savings which are generated through preventing future BC/OC are considered lower 
in value. Our results show that both newer strategies are cost-effective compared to the 
current clinical-criteria/FH-based BRCA1/BRCA2 testing policy. Compared to Clinical-
criteria/FH-based BRCA1/BRCA2 testing, Clinical-criteria/FH-based panel testing for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is highly cost-effective: 
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ICER=£7,629.65/QALY or $49,282.19/QALY (0.04days life-expectancy gained). A 
population-based panel-testing strategy for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 
mutations is the most cost-effective strategy compared to current policy: 
ICER=£21,599.96/QALY (9.34days life-expectancy gained) or $54,769.78/QALY (7.57days 
life-expectancy gained). 
Results of the one-way sensitivity-analysis (Figure 2; Supplementary Figures 2 and 
3) indicate that for Strategies-B and A, model-outcomes are not impacted that much by 
different model parameters (Supplementary Tables 2 and 3), mutation prevalence, surgical 
prevention costs, utility-scores or treatment of OC/BC or cardiovascular disease. Despite 
varying parameters at extremes of their CIs/range, the model remains cost-effective at the 
<£30,000/QALY or $100,000/QALY thresholds. The model is cost-effective at the lower 
limits of RRSO (30%) and RRM (34%). 
PSA results (Figures 3 and 4) show that at £30,000/QALY WTP-threshold 
population-testing for all gene mutations (strategy-B) is the preferred strategy in 83.7% 
simulations and Clinical-criteria/FH-based panel-testing for all gene mutations (strategy-A) is 
preferred only in 16.2% simulations.  Correspondingly, in American women, strategy-B is the 
preferred strategy at $100,000/QALY WTP threshold in 92.7% simulations. A population-
testing strategy is more cost-effective than any clinical-criteria/FH-testing strategy, with 
strategy-B emerging as the most cost-effective. Taken together, this clearly indicates cost-
effectiveness and overall preference for a population testing approach for 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations in the general population.  
 Scenario analyses are presented in Table 3. The alternative strategies-A and B still 
remain cost-effective at the UK/USA WTP-thresholds compared to the current clinical 
strategy, even if there is no reduction in BC-risk from RRSO (ICER=£27,632.95/QALY or 
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$72,221.37/QALY) and for lower RRM and RRSO rates. Population-testing remains cost-
effective until the genetic-testing costs rise to £250/test or $772/test.  
 BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% 
BC and 3.2%/4.88% OC in UK/USA women: 657/655 OC cases and 2420/2386 BC cases 
prevented per million. The overall proportion and number of BC/OC cases prevented as well 
as excess cardiovascular deaths from general (non-Jewish) population-based 
BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is given in Table 4. 
 
DISCUSSION 
Our analysis for the first time addresses the important topical issue of cost-effectiveness of a 
population-based strategy for testing moderate/high-penetrance OC/BC gene mutations in the 
general population. It justifies cost differences for different interventions by providing 
QALY-based health outcomes. This is required to guide policy decisions on healthcare 
resource allocation for disease prevention. Our findings that a population-based genetic 
testing strategy for OC/BC gene mutations outperforms any clinical-criteria or FH-strategy, 
with 84%-93% simulations cost-effective on PSA (£30,000/QALY and $100,000/QALY 
thresholds) are extremely noteworthy. Such a population-based program implemented in 
women >30years could result in 17,505/65,221 fewer OC and 64,493/237,610 fewer BC 
cases in British/American women respectively. This can have a much greater impact on the 
burden of disease than any current treatment strategy. Our data also highlight the need to 
move from BRCA1/BRCA2 testing to panel-testing incorporating additional 
RAD51C/RAD51D/BRIP1/PALB2 mutations within a clinical-criteria/FH-based strategy 
itself. These results have important implications for clinical care and OC/BC prevention. 
They could also be valuable to program evaluators/managers, policy makers, and healthcare 
commissioners.  
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Long and Ganz (43) used our AJ decision-analysis model (22) to evaluate systematic 
BRCA1/BRCA2 testing in the general non-Jewish population and found it not to be cost-
effective (43). However, AJ estimates/parameters should not be used to evaluate general 
population-testing, which may be a reason their analysis gives apparently incorrect/different 
results. For example, they use AJ estimates for prevalence of FH of cancer. However, 
clinical/FH-criteria are far more stringent and prevalence of such individuals is much lower 
in the general compared to the AJ-population. These data were previously unpublished and 
obtained from the ABCFR control population for our analysis. Additionally our current 
model and analysis is different, more comprehensive; uses general non-AJ estimates and 
compares two new panel testing strategies to the current gold-standard of Clinical-
criteria/FH-based BRCA1/BRCA2-testing. 
Our analysis has several advantages. It fulfils various principles listed by NICE for 
economic analyses including preferred type of economic evaluation (28). We use NICE 
guideline and clinical criteria-based current BRCA1/BRCA2 testing policy as the best practice 
comparator. Additionally, QALYs are used to measure health effects, utilities are 
incorporated and costs and outcomes discounted at 3.5%. Model parameters are derived from 
well-established/proven information from the literature and up-to-date data from the 
PROMISE programme, GCaPPS study, and Australian BC registry. The time-horizon is 
sufficient to reveal important differences in costs and outcomes, and costs of pre-test 
counselling plus testing are included. Besides OC/BC outcomes we also included excess 
coronary deaths from premenopausal oophorectomy (26). To avoid over-estimating the 
advantages of population testing, we used conservative costs for OC/BC diagnosis, treatment 
and management of recurrence (44). The extensive sensitivity analysis presented adds rigour 
to the results. Costs of counselling, RRSO, chemoprevention and treatment of 
OC/BC/coronary disease do not influence overall results. Results remain cost-effective even 
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at extremes of BRCA1/BRCA2 prevalence/penetrance estimates. Our analysis also highlights 
the need for better precision around prevalence and penetrance estimates of 
RAD51C/RAD51D/BRIP1/PALB2 mutations as the CIs for these are extremely wide.  This 
requires further research.  
A limitation may be considering only cardiovascular mortality (not morbidity) from 
early oophorectomy. However, we include costs for all excess cardiovascular disease and 
one-way sensitivity-analysis shows these parameters don’t substantially impact results. 
Another limitation may be our exclusion of increased lung/colorectal cancer mortality from 
premenopausal oophorectomy reported in the Nurses Health Study (26). However, this 
finding was not validated/reproduced in the 337,802 women EPIC study (45). Additionally, 
this excess mortality is confounded by smoking/risk related behaviors. The NIH-AARP Diet 
and Health Study found oophorectomy associated increased lung cancer risk was limited to 
smokers (46). Additionally, cardiovascular risk can also be confounded by smoking. Besides 
cohort data show that RRSO is associated with an overall 77% reduction in all-cause 
mortality (47), which will further improve cost-effectiveness. Nevertheless, even if we 
assumed a higher all-cause mortality (1:8), the model remains cost-effective for population-
screening (ICER=£22,820/QALY and $58,561/QALY, 8.7 and 6.9 days life-expectancy 
gained).  
We assume a 71% uptake of genetic-testing. However, the true uptake in non-AJ 
women needs to be addressed in future studies. Acceptability/uptake of population-based 
panel-testing is being assessed by us in the PROMISE pilot study (48). Premature surgical 
menopause is associated with worse sexual-functioning and vasomotor symptoms without 
decreasing generic quality-of-life (49-52). While HRT ameliorates detrimental consequences 
of premature menopause, symptom levels are still higher than those retaining their ovaries  
(51).  This can be offset by reduced cancer worry, decrease in perceived risk, and high 
15 
 
satisfaction rates found with surgical prevention (49,50). These issues along with a small (~3-
4%) complication rate(53) should be part of informed consent and RRSO decision making 
process. While we assume 80% HRT compliance, the true compliance in a larger population-
based cohort remains to be determined. It is important for these women to have long-term 
follow-up and monitoring of bone/cardiovascular health and receive psychosexual support.  
The utility of concomitant hysterectomy along-with RRSO has been debated. 
Proponents of hysterectomy cite the benefits of estrogen-alone HRT (no increased BC/heart 
disease risk) (54) and avoiding cervical smears. The impact and context of HRT in women 
undergoing premenopausal oophorectomy is completely different to that of older post-
menopausal WHI women. Short-term HRT in BRCA1/BRCA2 carriers undergoing 
premenopausal oophorectomy doesn’t increase BC-risk (55). HRT is protective for heart 
disease in premenopausal oophorectomized women (26,27), will be stopped at 50years (age 
of menopause), and does not increase cardiovascular risk in the post-menopausal post-
intervention phase (54). Hysterectomy has higher morbidity, complication rates, costs, longer 
operating time and hospital stay/recovery. Hysterectomy is not routinely offered as an 
alternative to progesterone HRT or to Tamoxifen in BC. With Tamoxifen (the absolute 
increase in endometrial-cancer (EC) risk is small (56),  and ACOG/RCOG guidelines only 
recommend urgent investigation of unscheduled/abnormal bleeding.(57,58). Recent reports 
suggest increased ‘serous’-EC risk in BRCA1 (59,60). However, serous-EC comprises ~7% 
of overall-EC (61), number of cases were small, CIs wide, absolute EC-risk (~3%) remains 
small, and overall EC-risk is not statistically significantly increased (59,60).. A recent cost-
effectiveness analysis had limitations. It only included women undergoing mastectomy and 
lacked a disutility for hysterectomy (62). Further corroborating data are needed and the issue 
of hysterectomy may then need revisiting. The risk-benefit profile doesn’t currently justify 
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routine hysterectomy at RRSO for OC-risk reduction(63), and most centres don’t practice 
this. 
In line with a number of analyses in high (2,64,65) and low-risk (66) women our 
base-model incorporates a reduction in BC-risk with pre-menopausal oophorectomy. 
Conversely, a recent Dutch article (67)  found no such effect. However, the follow-up was 
short (3.2years)(67), and longer follow-up data are awaited.. Nevertheless, our scenario 
analysis reconfirms cost-effectiveness of strategy-A and strategy-B even if pre-menopausal 
oophorectomy doesn’t decrease BC-risk. RAD51C/RAD51D/PALB2 have been considered 
as single cancer genes only. However, should future evidence show both increased OC and 
BC, it would increase cost-effectiveness of population-testing.  
Our model incorporates the impact of breast screening already prevalent and RRM. 
While RRM is weighted for a 21% complication rate, any reduction in QALYs is not 
included. Although RRM is linked with a negative impact on body-image and sexual 
pleasure, no detrimental impact on sexual-activity, habit, discomfort (68), anxiety, depression 
or quality-of-life was reported (68-70). Besides, adverse consequences may be balanced by 
decreased anxiety, increased social activity(68) and high cosmetic satisfaction rates (69,71-
73). 
Genomic, clinical and biological information is being combined through precision-
medicine initiatives like the 100,000-Genomes (74) and Moonshot (75) projects to optimise 
clinical decisions for personalized treatment. . Importantly these advances also offer the 
opportunity for personalised cancer prevention. This can have a much bigger impact on 
reducing burden of disease but requires a shift in focus to the unaffected population. We 
show for the first time that introduction of systematic genetic-testing in the general 
population for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is a cost-
effective strategy that can reduce OC and BC incidence and save lives. This form of panel-
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testing can potentially be expanded to include other gene mutations with established ‘clinical-
utility’ for cancer prevention. Our findings pave the way for research studies in carriers 
ascertained through population means to evaluate and understand impact on psychological-
health, quality-of-life, long-term health behaviour and reconfirm uptake rates of 
screening/surgical prevention strategies. Additionally big services re-design and 
implementation issues affecting major system change/intervention outcomes (76,77) need 
addressing before introducing such a programme. Furthermore, a robust system/platform for 
monitoring and re-classifying (as required) variants of uncertain-significance (VUS) detected 
needs establishing. Other issues that need addressing include raising public/health 
professional awareness, education, delivery logistics, quality-control, call-recall mechanisms 
and fail-safe checks/processes for quality assurance. All these have additional costs. Further 
development/expansion of co-ordinated/integrated clinical pathways between primary and 
tertiary care involving GPs, geneticists, gynaecologists, breast teams are needed for managing 
high-risk women. Given extreme cost-effectiveness  (78), of AJ-population BRCA-testing, 
panel-testing incorporating additional OC/BC genes would be cost-effective too and should 
be considered. The global cancer burden is expected to rise by 75%(79) and the number of 
BC/OC cases by 24%/27% in the UK and 34%/39% in the USA respectively by 2035 (80). 
Cancer prevention is key to achieve long-term transformational change and cost-efficiencies 
in our health-system. It is important we seize the opportunity offered to facilitate 
implementation of genomics for cancer prevention in healthcare. 
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Tables 
 
Table-1: Probabilities of different pathways in the model* 
 
Probability  Value (95%CI) [Range] Description  Source  
P1 0.00677 (0.0059-0.0077) 
BRCA1/BRCA2 mutation 
prevalence in a general population  Jervis 2015(29) 
P2 0.47 (0.34-0.56) Probability that carrier will undergo RRM Evans 2009(81) 
P3 0.96 [0.8-0.96] Reduction in risk of ovarian cancer from RRSO 
Finch 2006,(1) 
Rebbeck 2009(2) 
P4 0.202 [0.17-0.28] 
Probability that BRCA1/BRCA2 
carrier without RRSO will get 
ovarian cancer 
Antoniou 2008 
BOADICEA,(82) 
Chen 2007(83) 
P5 
0.02 (0.001, 0.06) Probability that a non-carrier will get ovarian cancer CRUK 2015(84) 
0.0128 (0.0126- 0.0130) 
Probability that a non-carrier will 
get ovarian cancer – USA 
estimate 
SEER(85) 
P6 0.0098 (0.0047, 0.0179) 
Probability of having a positive 
FH  fulfilling non-AJ genetic 
testing criteria 
ABCFR data 
P7 0.1  
BRCA1/BRCA2 prevalence in 
those fulfilling clinical criteria or 
FH positive  individuals 
Current testing 
guideline 
P8  0.0056 (0.0049, 0.0066) 
BRCA1/2 Mutation prevalence in 
FH negative individuals 
Jervis 2015,(29) 
ABCFR data 
P9 0.911 (0.62-0.98) 
Reduction in breast cancer  risk 
from RRM without RRSO in 
BRCA1/2 carriers 
Rebbeck 2004(3) 
P10 0.644 [0.42-0.67] 
Probability that BRCA1/2 carrier 
without RRM will get breast 
cancer 
Antoniou 2008 
BOADICEA,(82) 
Chen 2007(83) 
P11 
0.129 [0.11-0.14] 
Probability that a non-BRCA1/2 
carrier will get breast cancer with 
screening 
CRUK 2015(84) 
0.124 (0.1236- 0.1249) 
Probability that a non-BRCA1/2 
carrier will get breast cancer with 
screening – USA estimate 
SEER(85) 
P12 0.55 (0.30-0.75) Probability that mutation carrier will follow-up with RRSO 
Manchanda 
2012(86) 
P13 0.49 (0.37-0.65) HR for breast cancer from RRSO alone in BRCA1/BRCA2 carrier Rebbeck 2009(2) 
P14 0.95 (0.78-0.99) 
Reduction in risk of breast cancer 
from RRM with RRSO in 
BRCA1/BRCA2 carriers 
Rebbeck 2004(3) 
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P15 0.002 (0.0003, 0.0036) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in unselected 
general population controls 
Song 2015,(14) 
Ramus 2015(13) 
P16 0.089 (0.05, 0.17) 
Probability that RAD51C, 
RAD51D, BRIP1 carrier without 
RRSO will get ovarian cancer  
Loveday 
2012,(10) 
Loveday 
2011,(11) Ramus 
2015(13) 
P17 0.94 (0.83-0.98) 
Reduction in ovarian cancer risk 
from RRSO in RAD51C, 
RAD51D, BRIP1 
Parker 2013(26) 
P18 0.62 (0.53-0.74) 
HR of breast cancer from RRSO 
alone in RAD51C, RAD51D, 
BRIP1 
Parker 2009(87) 
P19 0.0122 (0.0074, 0.017) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
positive (BRCA1/2 negative) 
individuals 
Song 2015,(14) 
Ramus 2015(13) 
P20 0.00186 (0.00023, 0.0034) 
RAD51C, RAD51D, BRIP1 
Mutation prevalence in FH 
negative individuals 
Song 2015,(14) 
Ramus 2015(13) 
and ABCFR data 
P21 0.0303 (0.011,0.043) Risk of mortality from CHD after RRSO Parker 2013(26) 
P22 0.8 (0.76,0.83) Compliance with HRT Read 2010(88) 
P23 0.71 (0·60–0·83) HR of breast cancer risk from chemoprevention Cuzick 2015(89) 
P24 0.163 (0.136, 0.19) Uptake of breast cancer chemoprevention Smith 2016(90) 
P25 0.00125 (0.0008, 0.0017) 
PALB2 Mutation prevalence in 
unselected general population 
controls 
Slavin 2017(30) 
P26 0.44 (0.34, 0.55) 
Probability that PALB2 carrier 
without RRM will get breast 
cancer 
Antoniou 
2014(17) 
P27 0.0089 (0.0079, 0.0099) 
PALB2 Mutation prevalence in 
FH positive (BRCA1/2 negative) 
individuals 
Buys 2017(91) 
P28 0.0012 (0.00073, 0.0016) 
PALB2 Mutation prevalence in 
FH negative individuals 
ABFCR data, 
Buys 2017(91), 
Slavin 2017(30) 
P29 0.0072 (0.0068, 0.0076) Excess risk of CHD after RRSO Parker 2013(26) 
*95%CI- 95% confidence interval, ABCFR- Australian Breast Cancer Family Registry, 
CHD- Coronary heart disease, CRUK- Cancer Research UK, FH- family history, HRT- 
hormone replacement therapy , RRSO- risk reducing salpingo-oophorectomy, RRM: Risk 
reducing Mastectomy. A detailed explanation of the various probabilities is given in 
Supplementary Table 1 
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Table 2.  Model Outcomes for the different genetic testing strategies: undiscounted and discounted Costs, Quality Adjusted Life Years 
(QALYs) and Incremental Cost-effectiveness Ratio (ICER) per QALY 
  Undiscounted Discounted  
 
Strategy 
Cost 
(UK=£, 
USA=$) 
Life 
years QALYs  
Cost 
(UK=£, 
USA=$) Life years QALYs  
ICER in 
£/QALY or 
$/QALY  
U
K
 E
st
im
at
es
 
*Standard FH based testing for 
BRCA1/BRCA2 mutations £4423.25 52.2850 52.0822 £1586.11 23.7621 23.6909 -* 
FH based testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations £4423.23 52.2851 52.0823 £1586.38 23.7621 23.6909 £7629.65 
Population testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations £4586.86 52.3107 52.1116 £1779.73 23.7693 23.6999 £21599.96 
U
SA
 E
st
im
at
es
 *Standard FH based testing for BRCA1/BRCA2 mutations $19252.85 52.5063 52.3139 $6795.73 23.8127 23.7478 -* 
FH based testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations $19253.14 52.5064 52.3140 $6797.35 23.8128 23.7479 $49282.19 
Population testing for 
BRCA1/BRCA2, RAD51C, 
RAD51D, BRIP1, PALB2 mutations $19515.76 52.5271 52.3386 $7207.90 23.8185 23.7553 $54769.78 
 
*Reference strategy.  FH- family history, QALY- Quality Adjusted Life Years, ICER- Incremental Cost-effectiveness Ratio 
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Table-3: Scenario Analysis: UK and USA model outcomes for different scenarios  
SCENARIO ANALYSIS 
  UK Estimates USA Estimates 
  Strategy A Strategy B Strategy A Strategy B 
 
SCENARIOS 
ICER/QALY 
(£) 
LE 
gained 
(days) 
ICER/QALY 
(£) 
LE 
gained 
(days) 
ICER/QALY 
($) 
LE 
gained 
(days) 
ICER/QALY 
($) 
LE 
gained 
(days) 
 No reduction in BC risk from 
RRSO (p13=1, p18=1) 9,540.39 0.04  27,632.95 7.8 57,693.62 0.04 72,221.37 6.5 
 Lowest cost-effective RRM 
(p2) uptake rate: p2=19% 
(UK), p2= 8% (USA) 16,564.53 0.03 29,985.08 7.3 151,005.84 0.024 99,851.74 5.6 
 Lowest cost-effective RRSO 
(p12) uptake rate: p12= 22% 
(UK), p2= 13% (USA) 7,298.79 0.03 29,970.42 6.4 71,788.24 0.024 99,969.56 4.1 
 Lower RRM (p2) plus RRSO 
(p12) cost-effective rates: UK 
(p2 = 36% & p12 = 36%); (p2 
= 32% & p12 = 32%) 9,965.86 0.03 29,984.88 6.8 93,684.20 0.03 99,653.60 4.8 
 Genetic Testing cost £250 or 
$772 (thresholds at which 
population testing remains 
cost-effective) 7,629.65 0.04 29,896.23   9.4 49,282.19 0.04 99,947.44 7.6 
 
Strategy-A: FH based testing for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutations 
Strategy-B: Population testing for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutations   
QALY- Quality Adjusted Life Years, ICER- Incremental Cost-effectiveness Ratio; LE – Life expectancy; RRM – Risk reducing mastectomy; 
RRSO – Risk reducing salpingo-oophorectomy; BC- breast cancer  
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Table 4. Overall impact of General (non-Jewish) Population Testing for 
BRCA1/BRCA2/ RAD51C/RAD51D/BRIP1/PALB2 mutations in women >30 years* 
Population Testing for BRCA1/BRCA2/ 
RAD51C/RAD51D/BRIP1/PALB2 mutations UK women USA women 
Proportion of BC cases prevented 1.86% 1.91% 
Number of BC cases prevented per million women 2420 2386 
Number of BC cases prevented in the total population 
(26.65M UK and 99.6M USA women) 64493 237610 
Number of deaths from BC prevented per million 
women 523 367 
Number of deaths from BC prevented in the total 
female population 13930 36591 
Proportion of OC cases prevented 3.20% 4.88% 
Number of OC cases prevented per million women 657 655 
Number of OC cases prevented in the total population 
(26.65M UK and 99.6M USA women) 17505 65221 
Number of OC deaths prevented per million  461 460 
Number of OC deaths prevented in the total female 
population 12298 45857 
Number of excess deaths from heart disease per 
million women 25 25 
Number of excess deaths from heart disease in the 
total population 
(26.65M UK and 99.6M USA women) 
666 2490 
 
*The estimated female population (non-Jewish) >30years ~26.65M in the UK(92,93) and 
99.6M in USA.(94,95). BC – breast cancer, OC – ovarian cancer, M – million 
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Figure Legends 
 
Figure 1. Decision Analysis Model.  The Right half of the model reflects a population-based 
approach to testing from BRCA1, BRCA2, RAD51C, RAD51D,BRIP1 and PALB2 mutations. 
The left half of the model reflects a clinical criteria/ family history based testing approach for 
the same. Each decision point in the model is called a ‘node’ and each path extending from a 
node is called a decision ‘branch’. Each branch represents a mutually exclusive course or 
outcome. Each decision is given a probability highlighted along the decision branch. The 
probabilities used in the model are explained in Table-1 and Supplementary Table-S1. Values 
for each outcome are calculated. Cancer incidence was estimated by summing the 
probabilities of pathways ending in ovarian or breast cancer. Final outcomes of each path 
include development of breast cancer (BC), ovarian cancer (OC), no breast/ovarian cancer 
(no OC or BC) and excess deaths from coronary heart disease (CHD).   
Abbreviations: BC- Breast Cancer, CHD- Coronary heart disease; OC-Ovarian Cancer; No 
OC or BC- No Ovarian Cancer or Breast Cancer developed., RRSO –Risk reducing salpingo-
oophorectomy; RRM – Risk reducing mastectomy; BRCA- BRCA1 & BRCA2; RAD+ - 
RAD51C, RAD51D & BRIP1 
 
 Figure 2. One way Sensitivity Analysis: Population screening for BRCA1, BRCA2, 
RAD51C, RAD51D, BRIP1 and PALB2 mutations in UK & USA women.  One-way 
sensitivity analysis for all probabilities, costs and utilities in terms of ICER of UK and USA 
Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and PALB2 
mutations, compared to a Clinical-criteria / FH-based approach for BRCA1 and BRCA2 
testing. Y-axis: Incremental cost-effectiveness ratio (ICER): Cost (£s or $s) per quality 
adjusted life year (QALY) (discounted). X-axis: Probability, cost and utility parameters in the 
36 
 
model. The model is run at both lower and upper values/limits of the 95% confidence interval 
or range of all probability parameters described in Table-1/methods; and both lower and 
upper values/limits of the cost and utility-score parameters given in Table 2. Costs are varied 
by +/- 30%. ‘Maximum value’ represents outcomes for upper limit and ‘minimum value’ 
represents outcomes for lower limit of the parameter.  
 
Figure 3. Probabilistic Sensitivity Analysis: UK women.  Probabilistic sensitivity analysis 
in which all model parameters/ variables are varied simultaneously across their distributions 
to further explore model uncertainty.  X-axis: Incremental cost-effectiveness ratio (ICER) in 
terms of Cost (£s))/QALY; Y-axis: Proportion of simulations. The results of 10,000 
simulations were plotted on a cost-effectiveness acceptability curve showing the proportion 
of simulations (Y-axis) that indicated that the intervention was cost-effective at different 
willingness to pay thresholds (X-axis). The dotted line in Fig 4, marks the proportion of 
simulations found to be cost-effective at the £30,000 UK threshold used by NICE. Bold line 
Curve – Standard Clinical-criteria/ Family-history based testing for BRCA1/BRCA2 
mutations. 
Curve A- Clinical-criteria/ Family-history based testing for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations  
Curve B - Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and 
PALB2 mutations  
At any given point on the WTP-threshold scale, the sum of proportion of cost-effective 
simulations for all three strategies is always =1. 
At the £30,000/QALY willingness to pay threshold, 16.2% simulations are cost-effective for 
Clinical-criteria/ Family-history based testing for all gene mutations (Curve A) and 83.7% 
simulations are cost-effective for population-testing for all gene mutations (Curve B).  
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A population-testing strategy is more cost-effective than any Clinical-criteria/FH-testing 
strategy 
 
Figure 4. Probabilistic Sensitivity Analysis: USA women.  Probabilistic sensitivity 
analysis in which all model parameters/ variables are varied simultaneously across their 
distributions to further explore model uncertainty.  X-axis: Incremental cost-effectiveness 
ratio (ICER) in terms of Cost ($s))/QALY; Y-axis: Proportion of simulations. The results of 
10,000 simulations were plotted on a cost-effectiveness acceptability curve showing the 
proportion of simulations (Y-axis) that indicated that the intervention was cost-effective at 
different willingness to pay thresholds (X-axis). The dotted line marks the proportion of 
simulations found to be cost-effective at the $100,000 USA willingness to pay (WTP) 
threshold. 
Curve with Bold Line – Standard Clinical-criteria/ Family-history based testing for 
BRCA1/BRCA2 mutations 
Curve A- Clinical-criteria/ Family-history based testing for BRCA1, BRCA2, RAD51C, 
RAD51D, BRIP1 and PALB2 mutations  
Curve B - Population-based screening for BRCA1, BRCA2, RAD51C, RAD51D, BRIP1 and 
PALB2 mutations  
At any given point on the WTP-threshold scale, the sum of proportion of cost-effective 
simulations for all three strategies is always =1. 
At the $100,000/QALY willingness to pay threshold, 5.8% simulations are cost-effective for 
Clinical-criteria/ Family-history based testing for all gene mutations (Curve A) and 92.7% 
simulations are cost-effective for population-testing for all gene mutations (Curve B).  
A population-testing strategy is more cost-effective than any Criteria/FH-testing strategy 
